Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14876034 | 0.84 | MEN1 (0.55) | ALDH1A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL30143437 | 0.84 | MEN1 (0.52) | ALDH1A1MEN1KMT2AMAPTCA12 | |
| SCHEMBL11327841 | 0.84 | HPGD (0.58) | ALDH1A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL7091522 | 0.83 | ALDH1A1 (0.67) | ALDH1A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL14876503 | 0.82 | CASP1 (0.52) | ALDH1A1MEN1KMT2AMAPTNPSR1 | |
| SCHEMBL4701921 | 0.82 | ALDH1A1 (0.52) | ALDH1A1MEN1KMT2AMAPTCA12 | |
| SCHEMBL12638925 | 0.81 | KMT2A (0.61) | ALDH1A1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL524126 | 0.81 | ALDH1A1 (0.67) | ALDH1A1MEN1KMT2AMAPTCA12 | |
| SCHEMBL5879642 | 0.81 | CDC25A (0.49) | ALDH1A1KMT2ANPSR1POLB | |
| SCHEMBL5879644 | 0.81 | CDC25A (0.49) | ALDH1A1KMT2ANPSR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167058-A1 | GPX4 COMPOUNDS AND COMPOSITIONS AND METHODS OF TREATMENT USING SAME | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-06-01 | — | — | US | disclosed |
| US-20230167058-A1 | GPX4 COMPOUNDS AND COMPOSITIONS AND METHODS OF TREATMENT USING SAME | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-06-01 | — | — | US | disclosed |
| WO-2022219485-A1 | A SCALABLE PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE GLYCINE TERT-BUTYL ESTER AND ITS SALT THEREOF | HIKAL LIMITED (IN) | 2022-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167058-A1 | GPX4 COMPOUNDS AND COMPOSITIONS AND METHODS OF TREATMENT USING SAME | GPX4, GPX1, AIFM2 | ALDH1A1 915/4885MEN1 1684/4885KMT2A 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.